ABSTRACT
Long-term clinical remissions of leukemia, after allogeneic hematopoietic stem cell transplantation, depend on alloreactive memory T cells able to self-renew and differentiate into antileukemia effectors. This is counterbalanced by detrimental graft-versus-host disease (GVHD). Induction of a selective suicide in donor T cells is a current gene therapy approach to abrogate GVHD. Unfortunately, genetic modification reduces alloreactivity of lymphocytes. This associates with an effector memory (T(EM)) phenotype of gene-modified lymphocytes and may limit antileukemia effect. We hypothesized that alloreactivity of gene-modified lymphocytes segregates with the central memory (T(CM)) phenotype. To this, we generated suicide gene-modified T(CM) lymphocytes with a retroviral vector after CD28 costimulation and culture with IL-2, IL-7, or a combination of IL-7 and IL-15. In vitro, suicide gene-modified T(CM) cells self-renewed upon alloantigen stimulation and resisted activation-induced cell death. In a humanized mouse model, only suicide gene-modified T cells cultured with IL-7 and IL-15 persisted, differentiated in T(EM) cells, and were as potent as unmanipulated lymphocytes in causing GVHD. GVHD was halted through the activation of the suicide gene machinery. These results warrant the use of suicide gene-modified T(CM) cells cultured with IL-7 and IL-15 for the safe exploitation of the alloreactive response against cancer.
Subject(s)
Genes, Transgenic, Suicide/immunology , Graft vs Host Disease/immunology , Immunologic Memory , Interleukin-15/pharmacology , Interleukin-7/pharmacology , Stem Cell Transplantation , T-Lymphocytes/immunology , Animals , Cell Death/genetics , Cell Death/immunology , Cell Differentiation/genetics , Cell Differentiation/immunology , Cells, Cultured , Genes, Transgenic, Suicide/genetics , Graft vs Host Disease/genetics , Graft vs Host Disease/therapy , Humans , Immunologic Memory/genetics , Interleukin-15/immunology , Interleukin-2/genetics , Interleukin-2/immunology , Interleukin-7/immunology , Isoantigens/genetics , Isoantigens/immunology , Lymphocyte Activation , Mice , Mice, Inbred NOD , Mice, SCID , Neoplasms/genetics , Neoplasms/immunology , Neoplasms/therapyABSTRACT
In allogeneic hematopoietic cell transplantation (allo-HCT), the immune recognition of host antigens by donor T lymphocytes leads to a beneficial graft-versus-leukemia (GvL) effect as well as to life-threatening graft-versus-host disease (GvHD). Genetic modification of T lymphocytes with a retroviral vector (RV) expressing the herpes simplex virus-thymidine kinase (TK) suicide gene confers selective sensitivity to the prodrug ganciclovir (GCV). In patients, the infusion of TK+ lymphocytes and the subsequent administration of GCV resulted in a time-wise modulation of antihost reactivity for a GvL effect, while controlling GvHD. Because activation required for genetic modification with RV may reduce antihost reactivity, we investigated the requirements for maximizing the potency of human TK+ lymphocytes. Whereas T-cell receptor triggering alone led to effector memory (EM) TK+ lymphocytes, the addition of CD28 costimulation through cell-sized beads resulted in the generation of central memory (CM) TK+ lymphocytes. In a quantitative model for GvHD using nonobese diabetic/severely combined immunodeficient mice, CM TK+ lymphocytes were more potent than EM TK+ lymphocytes. GCV administration efficiently controlled GvHD induced by CM TK+ lymphocytes. These results warrant the clinical investigation of CM suicide gene-modified human T lymphocytes for safe and effective allo-HCT.
Subject(s)
Genes, Transgenic, Suicide/immunology , Genetic Therapy , Graft vs Host Disease/therapy , Retroviridae , T-Lymphocytes/immunology , Thymidine Kinase/immunology , Viral Proteins/immunology , Animals , Antiviral Agents/administration & dosage , CD28 Antigens/immunology , Female , Ganciclovir/administration & dosage , Genes, Transgenic, Suicide/genetics , Graft vs Host Disease/genetics , Graft vs Host Disease/immunology , Graft vs Leukemia Effect/genetics , Graft vs Leukemia Effect/immunology , Hematopoietic Stem Cell Transplantation , Humans , Immunologic Memory , Mice , Mice, Inbred NOD , Mice, SCID , Receptors, Antigen, T-Cell/immunology , Simplexvirus/genetics , Simplexvirus/immunology , T-Lymphocytes/transplantation , Thymidine Kinase/genetics , Transplantation, Homologous , Viral Proteins/geneticsABSTRACT
Several pharmaceutical companies have developed an increasing number of second generation protease inhibitors (PI) during the last few years. Many of these compounds have been in preclinical trials and some are now in clinical use. All drugs in this category have been designed to be well absorbed and overcome the crucial problem of cross-resistance within this class of compounds. Taking into account the rapid occurrence of PI cross-resistance, clinicians who are treating patients with the HIV-1 infection will need new active PIs in the near future. The clinical and antiviral efficacy of the new molecules versus the older PIs will be investigated through comparative trials that are likely to be completed over the next 12 months. These third-generation PIs currently in development will be the subject of our review.